Search results

Filters
Close
ADDED DATE
Added date
AUTHOR Please select
TOPICS Please select
WATCH / LISTEN / READ TIME
Author(s): Ovidiu Chioncel , Sean P Collins , Stephen J Greene , et al Added: 3 years ago
Hospitalisation is a critical event in the clinical course of heart failure (HF) and despite relatively rapid relief of symptoms, hospitalisation is followed by an increased risk of death and re-hospitalisation.1 While performance measures have been developed in the last few years with the intent of improving post-discharge outcomes, post-discharge mortality rates remain unchanged or have… View more

Heart Failure
Author(s): Maria Rosa Costanzo Added: 3 years ago
Approximately 90% of the more than 1 million yearly heart failure hospitalisations in the US and Europe are a result of symptoms and signs of fluid overload and are associated with readmission rates of 24% and 50% at 30 days and 6 months, respectively.1,2 Recurrent heart failure-related hospitalisations have uniformly been associated with worse outcomes, independent of age and renal function.3 … View more

Heart Failure
Congestion and Diuretic Resistance in Acute or Worsening Heart Failure
Author(s): Ingibjörg Kristjánsdóttir , Tonje Thorvaldsen , Lars H Lund Added: 3 years ago
From Acute Heart Failure Towards Worsening or De Novo Heart Failure The natural history of heart failure (HF) is characterised by disease progression and episodes of worsening HF and acute decompensation requiring outpatient treatment intensification, emergency department or in-hospital care. Acute HF (AHF), also known as acute decompensated HF, is defined as a progressive and sometimes rapid… View more

Heart Failure
Red Cell Distribution Width as a Biomarker for Heart Failure: Still Not Ready for Prime-Time
Author(s): Sunil K Nadar , Muhammad Mujtaba Shaikh Added: 3 years ago
Dear Editor, We would like to thank García-Escobar and Ingelmo for their letter regarding our article on the use of biomarkers in routine clinical care for heart failure.1,2 It was with interest that we read their comments on the use of red cell volume distribution width (RDW) as another biomarker for use in the management of patients with heart failure. As mentioned in their letter, RDW is a… View more

Heart Failure
Author(s): Davide Stolfo , Gianluigi Savarese Added: 5 years ago
Heart failure (HF) is a major and growing public health problem with high morbidity, mortality and costs.1 Due to the ageing the population, the mean age of patients with HF is increasing and exceeds 70 years in most developed countries. HF prevalence rises with age and exceeds 10% in people over 80.2 Older patients are more frail and have a higher risk of cardiovascular events. They also have a… View more

Heart Failure
Acute Heart Failure in Coronavirus Disease 2019 and the Management of Comedications
Author(s): Chia Siang Kow , Syed Shahzad Hasan Added: 3 years ago
Dear Editor, We read, with great interest, the review article written by Oliveros et al. entitled ‘Coronavirus Disease 2019 and Heart Failure: A Multiparametric Approach’, which comprehensively summarises the clinical characteristics of cardiovascular complications associated with coronavirus disease 2019 (COVID-19) and the use of telehealth in patients with heart failure.1 This review should be… View more

Heart Failure

COVID-19
Sodium–Glucose Co-transporter 2 Inhibitors in Heart Failure: Recent Data and Implications for Practice
Author(s): Giuseppe Rosano , David Quek , Felipe Martínez Added: 3 years ago
Heart failure (HF) is a shared chronic phase of many cardiac diseases, including ischaemic heart disease, chronic obstructive pulmonary disease and hypertension. It is characterised by structural or functional impairment of ventricular filling or ejection of blood from the heart.1–3 It is estimated that there are more than 37.7 million cases of HF globally and its prevalence is on the rise.2 HF… View more

Heart Failure

Prevention & Chronic Conditions
Haemodynamic Balance in Acute and Advanced Heart Failure: An Expert Perspective on the Role of Levosimendan
Author(s): Piergiuseppe Agostoni , Dimitrios T Farmakis , Jose M García-Pinilla , et al Added: 3 years ago
The use of IV vasoactive drugs, diuretics, vasodilators and inotropes for correcting haemodynamic dysfunction in patients with decompensated heart failure has been described over many decades.1 However, data on their effects on prognosis do not offer a convincing picture of clinical benefit.2 This is particularly true regarding IV inotropes. Clinical data collected on the effects of cardiac… View more

Heart Failure
Author(s): A Mark Richards Added: 3 years ago
Ideally biomarkers provide the clinician with assistance in one or more of: (i) diagnosis, (ii) prognosis, (iii) choice and titration of therapy, (iv) monitoring progression of disease and (v) assessing response to treatment. The best-established biomarkers in acute decompensated heart failure (ADHF) are the B-type natriuretic peptides (brain natriuretic peptide [BNP] and N-terminal of the… View more

Heart Failure

Prevention & Chronic Conditions
GDMT for Heart Failure
Author(s): Edgar Francisco Carrizales-Sepúlveda , Alejandro Ordaz-Farías , José Arturo Vargas-Mendoza , et al Added: 1 month ago

Standards & Guidelines

Heart Failure